New drug combo shows promise for Hard-to-Treat breast cancer
Disease control
Ongoing
This study tested a combination of two drugs, pembrolizumab and fulvestrant, in 47 people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer. The goal was to see if the combination could shrink tumors or keep them stable for at least four months. T…
Phase: PHASE2 • Sponsor: Nancy Chan, MD • Aim: Disease control
Last updated May 22, 2026 14:02 UTC